CRISPR Therapeutics AG
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CRISPR Therapeutics AG (Nasdaq: CRSP) is a biotechnology company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. Founded in 2013 and headquartered in Zug, Switzerland, the company operates globally with research and development facilities in Boston and San Francisco, California, and a state-of-the-art manufacturing site in Framingham, Massachusetts. Its lead approved therapy, exagamglogene autotemcel (exa-cel, commercialized as CASGEVY in collaboration with Vertex Pharmaceuticals), is an autologous ex vivo CRISPR/Cas9 gene-edited cell therapy approved in multiple countries for eligible patients with sickle cell disease and transfusion-dependent beta-thalassemia; the company advances a broad pipeline including wholly owned and partnered programs across hemoglobinopathies such as next-generation conditioning agents and in vivo HSC editing; immuno-oncology and autoimmune therapies like CTX112 (anti-CD19 allogeneic CAR T) and other CAR T candidates targeting CD19, CD70, and glypican-3; in vivo cardiovascular programs including CTX310 (ANGPTL3), CTX320 (Lp(a)), and CTX340 (AGT for refractory hypertension); additional in vivo candidates such as CTX450 (ALAS1 for acute hepatic porphyria), CTX460 (SERPINA1 for alpha-1 antitrypsin deficiency), and undisclosed programs in rare and common diseases; regenerative medicine offerings like CTX211 and CTX213 (allogeneic gene-edited stem cell-derived therapies for type 1 diabetes); and partnered siRNA and other initiatives including SRSD107 (Factor XI for thromboembolic conditions with Sirius Therapeutics) and programs in Duchenne muscular dystrophy, myotonic dystrophy type 1, cystic fibrosis, and type 1 diabetes licensed to Vertex. In 2025, CRISPR Therapeutics expanded its portfolio through a strategic collaboration with Sirius Therapeutics, involving a $25 million cash upfront and $70 million equity investment to co-develop and commercialize novel siRNA therapies starting with SRSD107, with options for two additional programs and shared costs/profits; the company also continues global commercialization of CASGEVY, achieving regulatory approvals in nine countries and treating over 100 patients as of mid-2025 while advancing clinical milestones for CTX112, CTX310, CTX320, and others amid strong cash reserves exceeding $1.7 billion.
Company News
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
3 Trending Names Overtaking Wall Street Today
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?
CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head Survey
CRISPR Therapeutics (NASDAQ:CRSP) Stock: Insider James Kasinger Sells 10,400 Shares
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know